Records 1 - 3
| ERBB2 and KRAS alterations mediate response to EGFR inhibitors in early stage gallbladder cancer.
International journal of cancer 2018 Oct .
Iyer Prajish, Shrikhande Shailesh V, Ranjan Malika, Joshi Asim, Gardi Nilesh, Prasad Ratnam, Dharavath Bhasker, Thorat Rahul, Salunkhe Sameer, Sahoo Bikram, Chandrani Pratik, Kore Hitesh, Mohanty Bhabani, Chaudhari Vikram, Choughule Anuradha, Kawle Dhananjay, Chaudhari Pradip, Ingle Arvind, Banavali Shripad, Gera Poonam, Ramadwar Mukta R, Prabhash Kumar, Barreto Savio George, Dutt Shilpee, Dutt Am
| Mutational frequency of KRAS, NRAS, IDH2, PIK3CA, and EGFR in North Indian gallbladder cancer patients.
Ecancermedicalscience 2017 11 757.
Sharma Aarti, Kumar Ashok, Kumari Niraj, Krishnani Narendra, Rastogi Neer
| Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Jul 28 (21): 3491-7.
Lubner Sam J, Mahoney Michelle R, Kolesar Jill L, Loconte Noelle K, Kim George P, Pitot Henry C, Philip Philip A, Picus Joel, Yong Wei-Peng, Horvath Lisa, Van Hazel Guy, Erlichman Charles E, Holen Kyle